

Maternal Body-Mass Index and Cord Blood Circulating Endothelial Colony-Forming Cells

Rafael Moreno-Luna, PhD^{1,2,*}, Rocio Muñoz-Hernandez, BS^{2,*}, Ruei-Zeng Lin, PhD¹, Maria L. Miranda, MD, PhD², Antonio J. Vallejo-Vaz, MD², Pablo Stiefel, MD, PhD², Juan M. Praena-Fernandez, BS³, Jose Bernal-Bermejo, BS⁴, Luis M. Jimenez-Jimenez, MD, PhD⁵, Jose Villar, MD, PhD², and Juan M. Melero-Martin, PhD¹

Objective Endothelial colony-forming cells (ECFCs) are a subset of circulating endothelial progenitor cells that are particularly abundant in umbilical cord blood. We sought to determine whether ECFC abundance in cord blood is associated with maternal body-mass index (BMI) in nonpathologic pregnancies.

Study design We measured the level of ECFCs in the cord blood of neonates (n = 27) born from non-obese healthy mothers with nonpathologic pregnancies and examined whether ECFC abundance correlated with maternal BMI. We also examined the effect of maternal BMI on ECFC phenotype and function using angiogenic and vasculogenic assays.

Results We observed variation in ECFC abundance among subjects and found a positive correlation between prepregnancy maternal BMI and ECFC content ($r = 0.51$, $P = .007$), which was independent of other obstetric factors. Despite this variation, ECFC phenotype and functionality were deemed normal and highly similar between subjects with maternal BMI $<25 \text{ kg/m}^2$ and BMI between $25\text{--}30 \text{ kg/m}^2$, including the ability to form vascular networks in vivo.

Conclusions This study underlines the need to consider maternal BMI as a potential confounding factor for cord blood levels of ECFCs in future comparative studies between healthy and pathologic pregnancies. (*J Pediatr* 2014;164:566–71).

Endothelial colony-forming cells (ECFCs) are a subset of progenitor cells that circulate in peripheral blood and can give rise to endothelial cells,^{1,2} contributing to the formation of new vasculature and the maintenance of vascular integrity.^{3–5} The mechanisms that regulate the abundance of these cells in vivo remain poorly understood.

ECFCs are rare in adult peripheral blood.^{1,2,6} In contrast, there is an elevated number of these cells in fetal blood during the third trimester of pregnancy.^{7–9} Emerging evidence indicates that deleterious conditions during fetal life can impair ECFC content and function. For instance, offspring of diabetic mothers have been shown to have reduced number of circulating ECFCs and impaired cell functionality,¹⁰ which may contribute to the long-term cardiovascular complications. Similar observations have been reported in neonates with bronchopulmonary dysplasia.^{11,12}

The adverse association between maternal weight and the outcome of pregnancy is well known.^{13,14} Epidemiologic studies have shown that cardiovascular disease may have origins during fetal development.¹⁵ Excessive maternal pre-pregnancy weight and gestational weight gain are associated with adverse cardiovascular risk factors in the offspring.¹⁶ The fetal adaptations that occur in response to changes in maternal weight during pregnancy and whether these adaptations affect the level of ECFCs is completely unknown. In this study, we quantified the baseline variation in ECFC abundance and function among neonates born of non-obese healthy mothers with nonpathologic pregnancies and examined whether this normal variation was associated with differences in maternal weight.

Methods

Twenty-seven Caucasian mother-offspring pairs were included in this study. Exclusion criteria included pre-pregnancy obesity (ie, maternal body-mass index (BMI) $>30 \text{ kg/m}^2$), severe prepregnancy underweight (ie, maternal BMI $<16 \text{ kg/m}^2$), maternal infections, preexisting and gestational diabetes, hypertensive disorders of pregnancy, multiple gestation, asthma and/or respiratory diseases, thyroid disease,

From the ¹Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA; ²Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV); ³Unit of Counseling Statistics, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI), Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS); ⁴Unit of Clinical Gynecology, Obstetrics, and Pathology of the Women's Hospital, and ⁵Service of Clinical Biomedics, Hospital Universitario Virgen del Rocío, Seville, Spain
*Contributed equally.

Funded by the National Institutes of Health (R00EB009096 to J.M.-M.), Consejería de Salud de la Junta de Andalucía, Sistema Andaluz de Salud (SAS111241 to R.M.-L.), and the Instituto de Salud Carlos III FIS (PI10/02473 to P.S.). The authors declare no conflicts of interest.

0022-3476/\$ - see front matter. Copyright © 2014 Mosby Inc.
All rights reserved. <http://dx.doi.org/10.1016/j.jpeds.2013.10.063>

BMI	Body-mass index
ECFC	Endothelial colony-forming cell
FGF-2	Fibroblast growth factor-2
VE-cadherin	Vascular endothelial-cadherin
VEGF	Vascular endothelial growth factor




Figure 1. Association between maternal BMI and ECFC count in cord blood. **A**, Phase contrast micrograph of an ECFC colony. Arrowheads delimitate the border of the colony (scale bar: 200 μ m). **B**, Cumulative number of ECFC colonies at 4 weeks from 10 mL of cord blood (mean $\pm$ SE). **C**, ECFC abundance in cord blood from subjects with prepregnancy maternal BMI <25 kg/m² and 25-30 kg/m² (line represents median abundance). **D**, Univariate correlation between prepregnancy maternal BMI and ECFC count performed with Spearman rho test.

intrauterine growth retardation, and women who carried fetuses with chromosomal abnormalities or congenital malformations. The study included 5 preterm deliveries (<37 gestational weeks) that were not due to either maternal or fetal pathologies. This research was approved by the local ethics committee at the Hospital Universitario Virgen del Rocío. All the parents gave written informed consent for abstraction of data from their obstetric records and for the use of umbilical cord blood in accordance with the Declaration of Helsinki.

The following maternal and neonate data were obtained from the obstetric records: maternal age; mode of delivery (cesarean/vaginal delivery); mode of conception (natural/in vitro fertilization); parity (primipara/multipara); evidence of intrauterine meconium exposure; offspring sex; offspring birth weight; offspring birth height; maternal height; pre-pregnancy (6-8 weeks gestation) maternal weight; end-of-pregnancy (right before delivery) maternal weight; and postpartum (6 months postpartum) maternal weight. Gestational age was recorded according to the obstetricians' best estimate of gestation. Maternal BMI was calculated as the weight in kilograms divided by the square of the height in meters (kg/m²). Gestational weight gain was calculated as the difference between the weight at the end of pregnancy and the weight at first consultation. Postpartum weight retention was calculated as the difference between the weight at 6 months postpartum and the weight at first consultation. Maternal pre-pregnancy tobacco use was dichotomized into never- and ever-users.

Umbilical cord blood samples were collected ex utero using heparinized tubes. Cells were removed from plasma

by centrifugation for 5 minutes at 3000 rpm using a refrigerated centrifuge. The resulting supernatant (plasma) was apportioned into 0.5 mL aliquots and stored at -80 °C until analysis. Total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides were measured by enzymatic spectrophotometry using a Roche Cobas 8000 Modular Analyzer (Roche Diagnostics GmbH, Mannheim, Germany).

Cord blood samples (30–50 mL) were processed within 2 hours of blood collection. Mononuclear cells were obtained as previously described.^{17,18} Mononuclear cells were cryopreserved in aliquots equivalent to 10 mL cord blood as previously described¹⁸ and stored in liquid nitrogen for comparative analysis. Cryopreserved mononuclear cells were thawed in a 37 °C bath, thoroughly washed, and seeded on fibronectin-coated 6-well tissue culture plates (BD Bioscience, San Jose, California) using endothelial cell-medium (endothelial growth medium-2 without hydrocortisone, Lonza; 20% fetal bovine serum; 1 μ M glutamine-penicillin-streptomycin).¹⁷ Unbound cells were removed at 48 hours and the bound fraction maintained in endothelial cell-medium, with media being replenished every 2-3 days. Endothelial colonies were identified as well-circumscribed monolayers of ≥ 50 cells with cobblestone morphology. Colonies were enumerated on days 7, 14, 21, and 28 by visual inspection using an inverted microscope.

Endothelial cell phenotype was characterized by testing: (1) cloning-forming ability; (2) proliferation and migration towards vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2); and (3) regulation of




Figure 2. Assessment of ECFC phenotype. **A**, ECFCs express CD31, vWF, VE-cadherin, and uptake DiI-Ac-LDL. Cell nuclei were counterstained with DAPI (scale bar: 50 μ m). **B**, Quantitative RT-PCR analyses of ECFCs for endothelial (CD31, vWF, VE-cadherin, VEGF-R2, eNOS) and mesenchymal (CD90, PDGFR β) markers. **C**, Flow cytometric analysis of ECFCs for CD31, CD90, and CD45 (black line histograms). Isotype-matched controls are overlaid in solid gray histograms. **D**, Cloning-forming ability of ECFCs. The endothelial nature of the colonies was confirmed by binding of UEA-1 lectin (scale bar: 500 μ m). **E**, Outgrown colonies were categorized by size. Bars represent mean $\pm$ SE (n = 6). Ac-LDL, acetylated low-density lipoprotein; DAPI, 4',6-diamidino-2-phenylindole; eNOS, endothelial nitric oxide synthase; FITC, fluorescein isothiocyanate; mRNA, messenger RNA; MSCs, mesenchymal stem cells; PDGFR, platelet derived growth factor receptor; PE, phycoerythrin; UEA-1, Ulex europaeus agglutinin I; vWF, von Willebrand factor.

leukocyte adhesion upon inflammatory stimuli using methods previously described by our laboratory.¹⁹ The vasculogenic ability of ECFCs was evaluated in vivo using a previously developed xenograft model of human endothelial cell transplantation into immunodeficient mice.^{17,20} Animal experiments were conducted under a protocol approved by the Institutional Animal Care and Use Committee at Boston Children's Hospital.

Statistical Analyses

Data were analyzed with IBM SPSS v. 19.0 software (SPSS Inc, Chicago, Illinois). Categorical variables were expressed by absolute frequencies and percentages (n, %). Noncategorical variables were expressed by mean $\pm$ SD. Data from subjects in the maternal BMI <25 kg/m² group were compared with those in the 25-30 kg/m² group. Categorical variables were compared with Pearson χ^2 test except for tobacco use, which was analyzed with Fisher exact test. Non-categorical variables were compared with Mann-Whitney U tests except for

maternal age, which was normally distributed and was analyzed with 2-tailed unpaired Student *t* test. Shapiro-Wilk tests were used to determine normality. Univariate correlations were performed with use of Spearman correlation coefficient. Data from experiments performed in vitro and in mice were analyzed using GraphPad Prism v. 5 software (GraphPad Software Inc, La Jolla, California). These data were expressed as mean $\pm$ SE and means were compared using unpaired Student *t* tests. For all analyses, *P* < .05 was considered significant.

Results

Cord blood-derived ECFCs were identified in culture as outgrown colonies containing ≥ 50 endothelial cells (Figure 1, A). Colonies emerged in culture as early as 1 week, although the majority of the colonies appeared between 2 and 3 weeks (Figure 1, B), which is consistent with previous reports.¹ ECFCs were allowed to grow and were then purified by expression of CD31. The endothelial

Table. Obstetric characteristics according to pre-pregnancy maternal BMI*

	Maternal BMI						P value [‡]
	All subjects (n = 27)		<25 kg/m ² (n = 15)		25-30 kg/m ² (n = 12)		
Maternal							
Age (y)	30.4	5.7	30.7	5.6	30.1	6.0	.79
Primipara n (%)	18 (66.6)		10 (66.7)		8 (66.6)		.99
In vitro fertilization n (%)	2 (7.4)		2 (13.3)		0 (0.0)		.48
Cesarean delivery n (%)	3 (11.1)		2 (13.3)		1 (8.3)		.99
Tobacco use n (%)	11 (40.7)		5 (33.3)		6 (50.0)		.45
Gestational weight gain (kg)	12.6	4.8	12.2	2.7	13.0	6.7	.84
Postpartum weight retention (kg) [†]	0.0	4.4	0.6	4.1	0.7	4.9	.35
Neonatal							
Male n (%)	19 (70.4)		8 (53.3)		11 (91.6)		.04
Gestational age wk	38.8	2.3	38.8	1.6	38.7	3.0	.46
Preterm birth n (%)	5 (18.5)		2 (13.3)		3 (25.0)		.63
Birth weight kg	3.2	0.7	3.3	0.6	3.2	0.8	.88
Lipid profile in cord blood [†]							
Total cholesterol mg/dL	45.8	14.4	44.3	14.6	47.6	14.7	.58
HDL cholesterol mg/dL	20.2	7.2	20.2	7.3	20.2	7.4	.99
LDL cholesterol mg/dL	15.5	7.1	15.2	5.7	15.8	8.8	.84
Triglycerides mg/dL	26.4	12.9	25.2	12.2	27.7	14.0	.61

HDL, high-density lipoprotein; LDL, low density lipoprotein.

*Categorical variables are represented by absolute frequencies and percentages (n, %). Noncategorical variables are represented by mean ± SD.

†Values for postpartum weight retention and lipid profile are from n = 25 subjects.

‡P values are from comparison of the maternal BMI <25 kg/m² and the 25-30 kg/m² groups. Categorical variables were analyzed with Pearson χ^2 tests except for tobacco use, which was analyzed with Fisher exact test. Noncategorical variables were analyzed with Mann-Whitney U tests except for maternal age, total cholesterol, HDL, LDL that were normally distributed and were analyzed with Student t test.

phenotype of CD31-selected cells was verified via their expression of CD31 and vascular endothelial-cadherin (VE-cadherin) at the cell-cell borders, the expression of von Willebrand factor in a punctuate pattern in the cytoplasm, and specific affinity for uptake of acetylated low-density lipoproteins (Figure 2, A). Flow cytometry confirmed uniform expression of CD31 and negative expression of mesenchymal marker CD90 and pan-hematopoietic marker CD45 (Figure 2, C). Additionally, quantitative reverse transcription-polymerase chain reaction analyses showed the expression of endothelial markers CD31, vWF, VE-cadherin, VEGF-R2, and endothelial nitric oxide synthase at the messenger RNA level as well as the absence of messenger RNA transcripts of mesenchymal markers CD90 and PDGFR- β (Figure 2, B). Finally, colony-forming ability was confirmed at clonal density, which reflected the expected presence of highly-proliferative clonogenic cells in each ECFC population (Figure 2, D and E).

The abundance of ECFCs in each cord blood sample was determined after 4 weeks in culture. We found a median abundance of 6 colonies per 10 mL of cord blood with a broad 25th-75th IQR of 1.0-13 colonies. To address whether ECFC abundance was associated with maternal weight, we categorized the study into prepregnancy maternal BMI <25 kg/m²

(normal weight; n = 15) and 25-30 kg/m² (overweight; n = 12). We found that the level of these cells in cord blood was significantly higher in samples categorized as prepregnancy maternal overweight than in samples categorized as normal maternal weight, with median abundance of 12 and 3 colonies, respectively ($P = .01$; Figure 1, C). Moreover, multivariate regression analysis revealed a statistically significant positive correlation between maternal prepregnancy BMI and the level of ECFCs in the umbilical cord blood ($r = 0.51$, $P = .007$; Figure 1, D). This correlation remained statistically significant when maternal BMI was measured at both the end-of-pregnancy ($r = 0.45$, $P = .02$) and at 6 month postpartum ($r = 0.55$, $P = .004$). In contrast, we did not observe statistical association between ECFC abundance and gestational weight gain ($r = 0.02$, $P = .93$), the number of mononuclear cells in cord blood ($r = -0.08$, $P = .73$), or postpartum weight retention at 6 months ($r = 0.25$, $P = .23$). The correlation between ECFC count and maternal BMI was independent of other obstetric factors, including maternal age, mode of delivery, parity, prepregnancy use of tobacco, gestational age, offspring birth weight, and the lipid profile of the cord blood (Table). There were differences in the percentage of male/female offspring in each group. However, no statistical difference by sex was found ($P = .60$).

Our study included mostly term deliveries (Table) and, thus, we found no significant correlation between gestational age and ECFC content. Only when subjects were categorized as either preterm (<37 gestational weeks; n = 5) or term (≥ 37 weeks; n = 22), we did find differences in ECFC abundance (increased in preterm).

We then examined whether there were functional differences among ECFCs from subjects with maternal BMI <25 kg/m² and 25-30 kg/m². We found no statistical difference ($P > .05$) in: (1) the mitogenic and migratory response to angiogenic growth factors VEGF-A and FGF-2 (Figure 3, A and B); (2) the ability to assemble into capillary-like structures onto Matrigel (Figure 3, C); and (3) the ability to up-regulate leukocyte adhesion molecules E-selectin and intercellular adhesion molecule 1 upon exposure to the inflammatory cytokine tumor necrosis factor- α (data not shown) and the subsequent increase in leukocyte binding (Figure 3, D). We also found no statistical difference ($P > .05$) in the vasculogenic ability of ECFCs (Figure 3, E-H). Quantitative evaluation of microvessel density by histologic and flow cytometric methods revealed no statistical difference between the groups (Figure 3, G and H).

Discussion

ECFCs have enormous therapeutic potential because of their inherent proliferative and vasculogenic properties.^{17,21} However, current knowledge regarding what governs the abundance of these cells in vivo is still very limited.

The main implication of this study is the need to consider maternal BMI as a potential confounding factor for cord blood levels of ECFCs. Emerging evidence indicates that




Figure 3. Assessment of ECFC function. ECFCs were categorized into pre-pregnancy maternal BMI <25 kg/m² and 25-30 kg/m². **A**, Cell proliferation in response to VEGF-A (10 ng/mL) and FGF-2 (1 ng/mL). **B**, Cell migration in response to VEGF-A and FGF-2 expressed as percentage of gap closure. **C**, Capillary-like network formation on Matrigel expressed as total tube length per field. **D**, Adhesion of leukocytes onto ECFCs after stimulation with TNF- α (10 ng/mL). **E**, Vasculogenic properties of ECFCs compared in nude mice after subcutaneous implantation. H&E staining reveals numerous blood vessels (yellow arrowheads; scale bar: 100 μ m). **F**, Human-specific lumens confirmed by staining with UEA-1 (red) and perivascular coverage indicated by α -SMA (green) (white arrowheads; scale bars: 50 μ m). **G**, Microvessel density. **H**, ECFCs expressing UEA-1 and human CD31. Bars represent mean $\pm$ SE (n = 3 each group). α -SMA, α -smooth muscle actin; H&E, hematoxylin and eosin; TNF- α , tumor necrosis factor- α .

deleterious conditions during fetal life can impair ECFC content and function,^{10-12,22} and the level of these cells may vary extensively. Understanding what constitutes a normal baseline level of ECFC abundance will facilitate the interpretation of future comparative studies between pathologic and non-pathologic pregnancies.

Epidemiologic studies have shown that there is a relationship between BMI and several chronic conditions, including type 2 diabetes, hypertension, and coronary heart disease.²³ Although these risks are notably increased in obese subjects, there is also an approximately linear relationship between BMI and cardiovascular risks in nonobese subjects.²⁴ Additionally, excessive weight during gestation is generally associated with higher risk for negative neonatal outcomes.^{13,14} Considering that our study was focused on non-obese healthy mothers and with the limitation of not being able to establish a definitive cause-and-effect, we believe the correlation between maternal BMI and level of ECFCs in cord blood could be interpreted as a normal physiological adaptation that occurs in the rapidly growing fetus in order to maintain adequate formation of new vasculature and/or to preserve vascular integrity. Further studies will be needed to determine the mechanisms by which ECFCs are mobilized. Further studies also should

examine the influence of ethnic, environmental, and genetic factors on the association between maternal BMI and ECFCs in umbilical cord blood. ■

We thank Dan Lin and Dr Shou-Ching Jaminet (Center for Vascular Biology, Department of Pathology, Beth Israel Deaconess Medical Center) for quantitative reverse transcription-polymerase chain reaction analyses; Maria Jesus Dominguez-Simeon (Laboratorio de Hipertension Arterial y Lipidos), Rafael Torrejon, Lucas Cerrillo, and the study midwives (Servicio de Partorio de la Unidad Gestion Clinica de Ginecologia Obstetricia y Patologias Mamaras del Hospital de la Mujer, Hospital Universitario Virgen del Rocio) for assistance in the collection of umbilical cord blood samples.

Submitted for publication Jul 25, 2013; last revision received Sep 9, 2013; accepted Oct 10, 2013.

Reprint requests: Juan M. Melero-Martin, PhD, Department of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Enders 349, Boston, MA 02115. E-mail: juan.meleromartin@childrens.harvard.edu

References

- Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. *Blood* 2004;104:2752-60.

2. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. *Blood* 2007;109:1801-9.
3. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. *Blood* 2005;106:1525-31.
4. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. *Arterioscler Thromb Vasc Biol* 2008; 28:1584-95.
5. Yoder MC. Human endothelial progenitor cells. *Cold Spring Harb Perspect Med* 2012;2:a006692.
6. Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. *Circ Res* 2003;93:1023-5.
7. Baker CD, Ryan SL, Ingram DA, Seedorf GJ, Abman SH, Balasubramaniam V. Endothelial colony-forming cells from preterm infants are increased and more susceptible to hyperoxia. *Am J Respir Crit Care Med* 2009;180:454-61.
8. Javed MJ, Mead LE, Prater D, Bessler WK, Foster D, Case J, et al. Endothelial colony forming cells and mesenchymal stem cells are enriched at different gestational ages in human umbilical cord blood. *Pediatr Res* 2008;64:68-73.
9. Ligi I, Simoncini S, Tellier E, Vassallo PF, Sabatier F, Guillet B, et al. A switch toward angiostatic gene expression impairs the angiogenic properties of endothelial progenitor cells in low birth weight preterm infants. *Blood* 2011;118:1699-709.
10. Ingram DA, Lien IZ, Mead LE, Estes M, Prater DN, Derr-Yellin E, et al. In vitro hyperglycemia or a diabetic intrauterine environment reduces neonatal endothelial colony-forming cell numbers and function. *Diabetes* 2008;57:724-31.
11. Borghesi A, Massa M, Campanelli R, Bollani L, Tzialla C, Figar TA, et al. Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2009;180: 540-6.
12. Baker CD, Balasubramaniam V, Mourani PM, Sontag MK, Black CP, Ryan SL, et al. Cord blood angiogenic progenitor cells are decreased in bronchopulmonary dysplasia. *Eur Respir J* 2012;40:1516-22.
13. Cnattingius S, Bergstrom R, Lipworth L, Kramer MS. Prepregnancy weight and the risk of adverse pregnancy outcomes. *N Engl J Med* 1998;338:147-52.
14. Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. *Lancet* 2006; 368:1164-70.
15. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. *Lancet* 1989;2:577-80.
16. Fraser A, Tilling K, Macdonald-Wallis C, Sattar N, Brion M-J, Benfield L, et al. Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood. *Circulation* 2010;121:2557-64.
17. Melero-Martin J, Khan ZA, Picard A, Wu X, Paruchuri S, Bischoff J. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. *Blood* 2007;109:4761-8.
18. Lin R-Z, Dreyzin A, Aamodt K, Dudley AC, Melero-Martin J. Functional endothelial progenitor cells from cryopreserved umbilical cord blood. *Cell Transplant* 2011;20:515-22.
19. Lin R-Z, Moreno-Luna R, Zhou B, Pu WT, Melero-Martin J. Equal modulation of endothelial cell function by four distinct tissue-specific mesenchymal stem cells. *Angiogenesis* 2012;15:443-55.
20. Melero-Martin J, De Obaldia ME, Kang S-Y, Khan ZA, Yuan L, Oettgen P, et al. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. *Circ Res* 2008;103:194-202.
21. Traktuev DO, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, Saadatzaheh MR, Murphy M, et al. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. *Circ Res* 2009;104:1410-20.
22. Acosta JC, Haas DM, Saha CK, Dimeglio LA, Ingram DA, Haneline LS. Gestational diabetes mellitus alters maternal and neonatal circulating endothelial progenitor cell subsets. *Am J Obstet Gynecol* 2011;204:254. e8-e15.
23. Kopelman PG. Obesity as a medical problem. *Nature*. 2000;404:635-43.
24. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, et al. Weight, weight change, and coronary heart disease in women. Risk within the "normal" weight range. *JAMA* 1995;273:461-5.